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ABSTRACT  
Purpose: To characterize the role of EYS, a recently identified retinal disease gene, in 
families with inherited retinal degenerations in the Israeli and Palestinian populations. 
Methods: Clinical and molecular analyses included family history, ocular examination, 
full-field electroretinography (ERG), perimetry, autozygosity mapping, mutation detection, 
and estimation of mutation age. 
Results: We performed autozygosity mapping in 171 consanguineous Israeli and 
Palestinian families with inherited retinal degenerations. Large homozygous regions 
including the EYS gene were identified in 15 of the families. EYS mutation analysis in the 
15 index cases, followed by genotyping of specific mutations in additional 121 cases with 
inherited retinal degenerations, revealed five novel null mutations, two of which are 
founder mutations, in 10 Israeli and Palestinian families with autosomal recessive retinitis 
pigmentosa (arRP). The most common mutation we identified was a founder mutation in 
the Moroccan Jewish sub-population. Using the ESTIAGE program, we estimate that the 
age of the most recent common ancestor is 26 generations. The retinal phenotype in most 
patients was a typical yet relatively severe RP, with an early age of onset and non-
recordable ERGs upon presentation.  
Conclusions: Our results demonstrate that EYS is currently the most commonly mutated 
arRP gene in the Israeli population, mainly due to founder mutations. EYS mutations were 
associated with an RP phenotype in all patients, and we predict that the gene plays only a 
minor role in causing other retinal phenotypes. 
Page 2 of 29IOVS
 3 
INTRODUCTION 
Retinitis pigmentosa (RP), with a worldwide prevalence of about 1:3,500,
1-3
 is a group of 
hereditary degenerative diseases of the retina and is considered one of the most 
heterogeneous genetic diseases in humans. The disease appears with different modes of 
inheritance including autosomal recessive (50-60%), autosomal dominant (30-40%), or X-
linked (5-15%).
4
 A total of 25 genes have so far been described to cause non-syndromic 
autosomal recessive RP (arRP) and four additional loci have been identified by linkage 
studies (see the RetNet database at http://www.sph.uth.tmc.edu/RetNet/home.htm). In 1998, 
homozygosity mapping led to the identification of the RP25 locus in Spanish families.
5
 
Subsequent linkage analyses showed that additional families with arRP from various 
origins, including Pakistani
6
 and Chinese,
7
  were linked to the RP25 locus. Extensive fine 
mapping and sequencing efforts in the RP25 region led to a refinement of the linked 
region,
8
 and eventually to the identification of the causative gene simultaneously by two 
groups that used different gene hunting strategies.
9, 10
 Abd El-Aziz and co-workers used a 
multi-step analysis in which they excluded 60 of the 110 genes in the RP25 region, refining 
the locus to a 2.67 cM region, and identified a large genomic deletion in one of the linked 
families.
10
 Collin and co-workers, on the other hand, applied homozygosity mapping in 
non-consanguineous families, using genome-wide single nucleotide polymorphism (SNP) 
genotyping.
9
 The RP25 gene identified by both studies, termed EYS (eyes shut homolog), 
spans almost 2 Mb of genomic sequence and includes 44 exons coding for a 10,475 
nucleotide transcript. The gene is abundantly expressed in the human retina
9, 10
 and the 
protein is localized to the outer segments of the photoreceptor cells.
10
 The retinal function 
of the EYS protein is still unknown. It is a large protein, composed of 3165 amino acids, 
containing a signal peptide, 28 EGF-like and 5 laminin A G-like domains. The human EYS 
protein is a homolog of the Drosophila eyes shut (spacemaker) protein, which is an 
Page 3 of 29 IOVS
 4 
extracellular matrix protein essential for photoreceptor development and morphology of the 
insect eye.
11, 12
  
Eight EYS mutations, all of which are null, have been reported to date, in eight arRP 
families.
9, 10
 Most patients with EYS mutations had the clinical diagnosis of RP with an 
autosomal recessive inheritance pattern,
9, 10
 but interestingly, one patient had a cone-rod 
pattern of photoreceptor loss.
9
  
In a study aimed to estimate the prevalence of RP in the Israeli Jewish population, 
341,175 individuals aged 17-20 years were screened for visual acuity problems, and those 
who had less than 20/25 were further examined by an ophthalmologist.
13
 The prevalence in 
this study was estimated as 1:4,610.
13
 Since many RP patients in this age group have 
relatively preserved visual acuities, this is probably an underestimation. The Israeli and 
Palestinian populations serve as important genetic sources for identifying autosomal 
recessive disease genes since the Muslim population is enriched with consanguineous 
marriages and the Jewish population was divided into isolated ethnic groups during history, 
leading to relatively high inbreeding levels. A study conducted in schools for the blind in 
the West Bank and Gaza in 1992 concluded that 44-85% of the affected children 
(depending on location) were the offspring of a consanguineous marriage.
14
 Only limited 
information is currently available on the genetic causes of non-syndromic RP in the Israeli 
and Palestinian populations, with only a few mutations reported thus far in the CERKL, 
CRB1, NR2E3, RDH12, TULP1, and USH2A genes.
15-19
  
As part of our genetic analysis of Israeli and Palestinian families with autosomal 
recessive retinal degenerations, we used autozygosity mapping as the major mapping tool 
and identified families with arRP linked to the EYS region. Sequence analysis revealed five 
novel null mutations, two of which were founder mutations, in 10 families with arRP. The 
phenotype of most affected individuals was typical for arRP although some clinical 
variation was evident.  
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METHODS 
Patient recruitment: The tenets of the Declaration of Helsinki were followed and informed 
consent was obtained from all patients who participated in this study prior to donation of a 
blood sample. Blood samples for DNA analysis were obtained
 
from the index patient as 
well as other affected and unaffected family members.
  
Genetic analysis: Genomic DNA was extracted from peripheral blood samples of index 
cases and their family members using the FlexiGene DNA kit (QIAGEN). Whole genome 
SNP analysis was performed using the Affymetrix GeneChip Human Mapping 10K Xba 
142 2.0 microarray.  Primers for the screening of EYS by PCR amplification have been 
reported previously.
9
 PCR was performed in a volume of 25 l reaction with 35 cycles. 
Mutation analysis was performed by direct sequencing of purified PCR products. 
Genotyping of specific mutations was performed as follows: Two mutations, 
c.403delA,406G>T,410_424del15 (exon 4) and c.4361_4362CC>AG (exon 26) were 
genotyped using the restriction enzymes DdeI and MnlI, respectively. For the genotyping 
assay of the c.3715G>T (exon 25) mutation, we designed allele-specific primers to 
distinguish between the mutant and normal alleles (primer sequences available on request) 
and used the NlaIII enzyme for restriction analysis. The c.1211_1212insA (exon 8) and 
c.8218_8219delCA (exon 43) mutations were screened by sequencing analysis. The 
possible effect of sequence changes on the splicing of the corresponding exon was 
estimated using Splice Site Prediction by Neural Network at 
http://www.fruitfly.org/seq_tools/splice.html. 
Estimation of mutation age: We used the ESTIAGE program
20
 to calculate the age (in 
generations) of the most recent common ancestor of patients carrying the 
c.403delA,406G>T,410_424del15 mutation. ESTIAGE is a likelihood-based method which 
uses multi locus marker data from patients carrying the same mutation, assuming they 
descended from a common ancestor who introduced the mutation. An estimate of the 
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number of generations since the most recent common ancestor is obtained from the size of 
the haplotype shared by the individuals on each side of the disease locus. The method uses 
the haplotype information in patients carrying the mutation and in controls to identify the 
most likely positions of recombination events on the ancestral haplotype. This method was 
reported to be efficient for a very small number of affected individuals in rare diseases. We 
used SNP genotyping data from 36 markers on eight chromosomes carrying the mutation 
and 46 population-matched control chromosomes. Allele frequencies were calculated based 
on the control population. 
Clinical evaluation: Complete ophthalmic examinations were performed including 
refraction, visual acuity, biomicroscopic slit lamp examination, funduscopy. Retinal 
imaging included color fundus photographs, optical coherence tomography (OCT) and 
autofluorescence. Best corrected visual acuity was measured in each eye separately using 
an ETDRS chart, and presented as a decimal ratio. In patients with visual acuity lower than 
0.05, the distance at which fingers could be reliably counted was recorded. Retinal function 
was evaluated according to the level of patient cooperation by full-field electroretinography 
(ERG), Goldmann kinetic and/or Humphrey static Perimetry as previously described.
21
 
Briefly, full-field ERGs were recorded using corneal electrodes and a computerized system 
(UTAS 3000, LKC, MD). In the dark-adapted state, rod responses to a dim blue flash 
(Wratten 47b) and mixed cone-rod responses to a white flash (2.35 cd·sec/m2) were 
acquired. Cone responses to 30 Hz flashes of white light (9.4 cd·sec/m2) were acquired 
under a background light of 21 cd/m2. All ERG responses were filtered at 0.3-500 Hz and 
signal averaging used.  
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RESULTS 
Autozygosity mapping and EYS mutation analysis 
We recruited 712 Israeli and Palestinian families with hereditary non-syndromic retinal 
disease, 307 (including 121 with RP and 43 with Leber congenital amaurosis [LCA]) of 
which were consanguineous. Aiming to identify the causative gene in the consanguineous 
families, we used the 10K Affymetrix SNP microarray system for autozygosity mapping in 
patients from 171 of the families (82 with RP, 28 with LCA, and 61 with cone-dominated 
diseases). Autozygosity analysis revealed 18 patients from 15 different families (Table 1) 
who had a large homozygous region harboring the recently identified EYS gene and 
fulfilled two criteria: the genetic size of the homozygous region was at least 10 cM and it 
was among the 10 largest homozygous regions in the affected individual (Table 1). 
Interestingly, patients from three of the families (MOL0318, MOL0501, MOL0662- Fig. 1) 
were of Moroccan Jewish ancestry and shared a large region covered by 44 consecutive 
homozygous SNP markers. Sequence analysis of the 44 EYS exons and exon-intron 
boundaries in the 15 above-mentioned index cases revealed two novel homozygous null 
mutations in 4 families (Table 1 and Fig. 2). Patients from the three above-mentioned 
Moroccan Jewish families were homozygous for a novel complex frameshift mutation 
c.403delA,406G>T,410_424del15 (hereafter referred to as p.Thr135LeufsX25) in exon 4, 
which causes a premature stop codon at position 160 due to a single base pair deletion 
followed by a 15-bp deletion (Fig. 2A). In addition, an isolated case from a consanguineous 
Palestinian Muslim family (MOL0410; Fig. 1 and Table 1) was homozygous for a novel 
nonsense mutation, c.4361_4362CC>AG (p.Ser1454X), in exon 26 of the EYS gene (Fig. 
2D). Aiming to assess the frequency of these mutations among patients from the 
corresponding sub-populations, we screened a set of 56 Jewish families with RP from 
North-African ancestry (from Morocco, Libya, Tunisia, and Algeria) for the 
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p.Thr135LeufsX25 mutation and 47 Muslim families with RP for the p.Ser1454X mutation. 
The analysis revealed four additional index patients who were either heterozygous (TB59 
III:1 and MOL0626 III:1; Fig. 1 and Table 1) or homozygous (MOL0792 II:2 and 
MOL0806 III:7) for the p.Thr135LeufsX25 mutation.  
The two heterozygous patients were from non-consanguineous families, and we 
therefore assumed that the patients are compound heterozygous. Screening of the EYS gene 
indeed revealed novel heterozygous null mutations in these patients. Patient MOL0626 III:1 
(from Moroccan Jewish ancestry) was heterozygous for a frameshift mutation, 
c.1211_1212insA (p.Asn404LysfsX2; Table 1 and Fig. 2B), in exon 8. No additional family 
members were available to confirm the compound heterozygous state. Aiming to evaluate 
the frequency of the c.1211_1212insA mutation in North African Jewish RP patients, we 
sequenced exon 8 in 47 additional index RP patients, but none of them carried the 
c.1211_1212insA mutation or any other mutation in this exon. Patient TB59 III:1 was 
heterozygous for a novel frameshift mutation, c.8218_8219delCA (p.His2740TyrfsX27; 
Fig. 2E), in exon 43. Cosegregation analysis in family TB59 (Fig. 1) revealed that the 
p.Thr135LeufsX25 mutation was on the maternal allele (of Moroccan Jewish ancestry) and 
the c.8218_8219delCA mutation was on the paternal allele (of Iraqi Jewish ancestry). We 
therefore evaluated the frequency of the c.8218_8219delCA mutation in 31 Oriental Jewish 
RP patients (mainly from Iran, Iraq, and Afghanistan) and identified two non-
consanguineous patients from Iraqi Jewish origin who were either homozygous (MOL0640 
II:1) or heterozygous (TB24 III:2) for the mutation. All the alleles carrying the 
c.8218_8219delCA mutation were from an Iraqi Jewish origin and shared an identical 
haplotype within EYS, indicating a founder mutation. Sequencing analysis of the remaining 
exons in TB24 III:2 revealed yet another novel nonsense mutation, c.3715G>T 
(p.Glu1239X), in exon 25 (Table 1 and Fig. 2C). The mutation could not be identified in 
any of 31 additional RP patients from Oriental Jewish origin. 
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In addition, we identified 29 sequence changes in our genetic screen, of which 14 
were nonsynonymous changes which are known polymorphisms in the SNP database 
(Supplementary Table). None of these sequence changes is likely to be pathogenic. 
 
Haplotype analysis and estimation of mutation age 
The most common EYS mutation identified in this study was the p.Thr135LeufsX25 
mutation identified in 7 RP families, all of Moroccan Jewish ancestry, indicating a founder 
effect. Screening of normal individuals of Moroccan origin revealed that one out of 94 
control individuals was heterozygous. Haplotype analysis of four patients who were 
homozygous for this mutation revealed a shared homozygous region composed of nine SNP 
markers covering 3.2 Mb or 2.1 cM (Supplementary Fig. 1). The shared homozygous 
region in three of these patients from consanguineous families is much larger, harboring 44 
markers along a region of 17 Mb (6.3 cM). Two pieces of evidence suggest that the 
mutation is relatively young: the relatively large size of the shared homozygous region and 
the fact that the mutation was found only in Moroccan Jews and not in Jews originating 
from neighbouring countries (Algeria, Libya, and Tunisia). Aiming to estimate the mutation 
age, we used genotyping data from 36 SNP markers (8 within the EYS gene and 28 flanking 
it) on eight chromosomes carrying the mutation (MOL0318 II:13, MOL0318 III:2, 
MOL0501 II:1, and MOL0662 IV:1) and 46 population-matched control chromosomes. 
The data set was analyzed using the ESTIAGE software (see Methods) and the number of 
generations since the most recent common ancestor was estimated as 26 (95% CI of 12-56 
generations) or 650 years (based on a mean generation time of 25 years). 
 
Ocular phenotype associated with EYS mutations 
We clinically examined 15 patients with EYS mutations and performed ERG testing in 11   
(Table 2). All patients with EYS mutations showed characteristic manifestations of RP, with 
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a relatively severe course of disease. Night vision, visual fields, and ERG responses were 
markedly impaired already at early ages. Both myopic and hyperopic refractive errors were 
present. Fundus appearance was typical for RP including bone spicule-like pigmentation, 
pallor of the optic discs, and narrowing of blood vessels (representative fundus mosaics of 
the left eyes of patient TB24 III:2 at age 63 and patient MOL0501 II:3 at age 52 are shown 
in Fig. 3A and 3E, respectively). Macular involvement is evident also on autofluorescence 
imaging (Fig. 3B,F) and OCT, with retinal thinning and atrophy (Fig. 3D,H). Visual fields 
in these two patients are markedly constricted (Fig. 3C,G). In almost all patients for whom 
ERG data were available (ages between 19-51 years), both scotopic and photopic full-field 
ERG responses were extinguished, indicating severe retinal involvement (Table 2). Only in 
one patient (MOL0640 III:1) scotopic as well as photopic ERG responses were measurable, 
although also severely reduced. This patient initially presented with sector RP at the age of 
25 (based on funduscopic and visual field findings) which later progressed to widespread, 
generalized retinal involvement. The mean 30 Hz cone flicker ERG amplitude measured at 
our center on the first ERG test performed in each patient was significantly lower in the 
EYS group as compared to pooled, first test-ERG amplitudes in RP patients in our 
population (Fig. 4). The EYS group included 11 patients with a mean age of 34 years and 
mean ± SD amplitude of 0.65 µV ± 2.17. The control RP group included 240 patients with 
a mean age of 29.8 years and mean ± SD amplitude of 17.7 µV ± 22.2 (p-value for cone 
flicker ERG amplitude difference < 0.01).  
 
DISCUSSION 
EYS represents a major arRP gene, as can be appreciated from the widespread ethnic origins 
of families with arRP due to EYS mutations thus far reported.
9, 10
 In the present study, we 
show that mutations in EYS are currently the most frequent cause of non-syndromic arRP in 
the Israeli population, mainly due to founder mutations in two ethnic groups: Moroccan and 
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Oriental Jews. The five novel EYS mutations reported here account for at least 7% of arRP 
families (10 out of 141 families) we have thus far recruited from the Israeli and Palestinian 
populations. The most common mutation we identified in this study (p.Thr135LeufsX25) is 
a founder mutation in the Moroccan Jewish population accounting for about 19% (12 out of 
64 chromosomes) of non-syndromic arRP alleles in this population, and is therefore 
currently the most common cause of RP in Jews of Moroccan ancestry.  
Similar to previous studies, most of our patients with EYS mutations manifested 
typical and rather severe arRP. One exception is an isolated case who initially presented 
with a milder phenotype, sector RP, and was homozygous for a null mutation in exon 43. 
Although one might expect that the nonsense-mediated mRNA decay (NMD) mechanism 
would prevent protein production of this mutant allele, it is tempting to speculate that some 
transcripts will escape degradation, as reported in many other cases (see Holbrook et al.
22
 
for review), manifesting a milder, more localized, phenotype. Mutations that are likely to 
result in a similar effect, however, were reported to cause the typical widespread and severe 
RP phenotype.
9
 Only one patient to date was reported to manifest a different retinal 
phenotype, cone-rod dystrophy (CRD), due to a null mutation located at the very end of the 
carboxy-terminus of EYS, thereby resulting in the absence of only the last 10 amino acids. 
His older sib, though, displayed RP even suggesting the possibility of variable intrafamilial 
expression of certain mutations,
9
 probably due to other factors influencing clinical 
expression. We included 61 families with AR cone dominated diseases (mainly CRD) in 
our autozygosity analysis, but only one (in which no EYS mutations were identified) was 
homozygous at the EYS locus, indicating that mutations in EYS are a rare cause of CRD in 
our population. The clinical variability in patients with null mutations in EYS suggests that 
other factors contribute to the severity of disease in these cases, as previously suggested.
9
 
It is interesting to note that all EYS mutations thus far reported,
9, 10
 as well as the 
five novel mutations reported here, are null mutations (either frameshift or nonsense). A 
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large number of EYS missense changes are known (some of which appear as entries at 
dbSNP), but none of which is currently considered as a cause of disease. Such missense 
changes, in combination with a null mutation on the counter allele, might result in a milder 
retinal phenotype. Another possible explanation for the lack of pathogenic missense 
mutations in EYS is the ability of the protein to tolerate single amino-acid alterations, 
affecting only a specific protein domain, due to the multiple functional domains (e.g. EGF-
like and laminin A G-like domains) in the EYS protein. This phenomenon resembles the 
mutation spectrum of well-studied retinal genes, including CHM
23
 and the RPGR-ORF15 
terminal exon,
24-26
 in which only null mutations have been reported so far. Such genes will 
therefore cause a retinal phenotype only if no protein is generated. One can also assume that 
some of the polymorphic missense changes might result in an expressed protein with 
reduced activity. This makes EYS an attractive candidate for modulating retinal disease 
severity in cases caused by mutations in other retinal genes, mainly those encoding proteins 
that interact with EYS, such as PROM1.
9
 Since EYS was only recently identified, further 
EYS mutation analyses are likely to result in a more accurate and comprehensive EYS 
mutation spectrum.  
The most common mutation we identified here (p.Thr135LeufsX25) is a founder 
mutation in the Moroccan Jewish sub-population. The history of the Jewish population in 
North Africa (including Morocco, Algeria, Libya, and Tunisia) is ancient and complicated. 
The population was founded about 2,000-2,600 years ago and since then underwent a 
number of historic events that had a dramatic effect on the population size, including a few 
waves of immigrations (during the first temple period about 600 years BCE and in 1492 
due to the expulsion from Spain), the conversion of Berber tribes to Judaism (during the 
sixth and seventh centuries), and the persecution of a major part of the community in 1033 
and 1232. By 1948, the Jewish Moroccan population (the major North African Jewish 
population) was estimated to contain 270,000 individuals, most of whom immigrated to 
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Israel once the state was established in 1948. Using the ESTIAGE program, which was 
designed for rare diseases, we estimated the age of the most recent common ancestor to be 
relatively young, 26 generations (or 650 years) ago. This young age is supported by the fact 
that the mutation was found in Jews originated from Morocco (and not other North African 
countries), and by the relatively large size of the shared homozygous region in most of the 
studied patients. Up to date, the estimated ages of only two founder mutations in the 
Moroccan Jewish population have been reported and found to be relatively ancient (2,600-
2,700 years ago).
27, 28
  
In summary, in this study we report the mutation spectrum of EYS in a cohort of 
Israeli and Palestinian RP patients which includes five novel mutations and show that EYS 
is the most frequently mutated arRP gene currently known in the Israeli population.  
 
 
Page 13 of 29 IOVS
 14 
ACKNOWLEDGEMENTS 
 
We thank the patients and their families for participating in this study. We thank Ms. Lina 
Bida, Ms. Ruhama Neis, Mrs. Inbar Erdinest and Dr. Alex Obolensky for excellent 
technical assistance. This work was supported by the Foundation Fighting Blindness (FFB- 
grant number BR-GE-0607-0395-HUJ), the Stichting Wetenschappelijk Onderzoek 
Oogziekenhuis Prof. Dr. H.J. Flieringa, Rotterdam, and the Yedidut 1 Research Fund. 
 
 
Page 14 of 29IOVS
 15 
REFERENCES 
1. Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH. Prevalence of 
retinitis pigmentosa in Maine. Am J Ophthalmol. 1984;97:357-365. 
2. Rosenberg T. Epidemiology of hereditary ocular disorders. Dev Ophthalmol. 
2003;37:16-33. 
3. Bundey S, Crews SJ. A study of retinitis pigmentosa in the city of Birmingham. II 
Clinical and genetic heterogeneity. J Med Genet. 1984;21:421-428. 
4. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795-
1809. 
5. Ruiz A, Borrego S, Marcos I, Antinolo G. A major locus for autosomal recessive 
retinitis pigmentosa on 6q, determined by homozygosity mapping of chromosomal 
regions that contain gamma-aminobutyric acid-receptor clusters. Am J Hum Genet. 
1998;62:1452-1459. 
6. Khaliq S, Hameed A, Ismail M, et al. Refinement of the locus for autosomal 
recessive Retinitis pigmentosa (RP25) linked to chromosome 6q in a family of 
Pakistani origin. Am J Hum Genet. 1999;65:571-574. 
7. Abd El-Aziz MM, El-Ashry MF, Chan WM, et al. A novel genetic study of Chinese 
families with autosomal recessive retinitis pigmentosa. Ann Hum Genet. 
2007;71:281-294. 
8. Abd El-Aziz MM, Barragan I, O'Driscoll C, et al. Large-scale molecular analysis of 
a 34 Mb interval on chromosome 6q: major refinement of the RP25 interval. Ann 
Hum Genet. 2008;72:463-477. 
Page 15 of 29 IOVS
 16 
9. Collin RWJ, Littink KW, Klevering BJ, et al. Identification of a 2 Mb human 
ortholog of Drosophila eyes shut/spacemaker that is mutated in patients with 
retinitis pigmentosa. Am J Hum Genet. 2008;83:594-603. 
10. Abd El-Aziz MM, Barragan I, O'Driscoll CA, et al. EYS, encoding an ortholog of 
Drosophila spacemaker, is mutated in autosomal recessive retinitis pigmentosa. Nat 
Genet. 2008;40:1285-1287. 
11. Husain N, Pellikka M, Hong H, et al. The agrin/perlecan-related protein eyes shut is 
essential for epithelial lumen formation in the Drosophila retina. Dev Cell. 
2006;11:483-493. 
12. Zelhof AC, Hardy RW, Becker A, Zuker CS. Transforming the architecture of 
compound eyes. Nature. 2006;443:696-699. 
13. Rosner M, Hefetz L, Abraham FA. The prevalence of retinitis pigmentosa and 
congenital night blindness in Israel. Am J Ophthalmol. 1993;116:373-374. 
14. Elder MJ, De Cock R. Childhood blindness in the West Bank and Gaza Strip: 
prevalence, aetiology and hereditary factors. Eye. 1993;7:580-583. 
15. Kaiserman N, Obolensky A, Banin E, Sharon D. Novel USH2A mutations in Israeli 
patients with retinitis pigmentosa and Usher syndrome type 2. Arch Ophthalmol. 
2007;125:219-224. 
16. Auslender N, Sharon D, Abbasi AH, et al. A common founder mutation of CERKL 
underlies autosomal recessive retinal degeneration with early macular involvement 
among Yemenite Jews. Invest Ophthalmol Vis Sci. 2007;48:5431-5438. 
Page 16 of 29IOVS
 17 
17. Bandah D, Merin S, Ashhab M, Banin E, Sharon D. The spectrum of retinal 
diseases caused by NR2E3 mutations in Israeli and Palestinian patients. Arch 
Ophthalmol. 2009;127:297-302. 
18. Abbasi AH, Garzozi HJ, Ben-Yosef T. A novel splice-site mutation of TULP1 
underlies severe early-onset retinitis pigmentosa in a consanguineous Israeli Muslim 
Arab family. Mol Vis. 2008;14:675-682. 
19. Benayoun L, Spiegel R, Auslender N, et al. Genetic heterogeneity in two 
consanguineous families segregating early onset retinal degeneration: The pitfalls of 
homozygosity mapping. Am J Med Genet A. 2009;15:650-656. 
20. Genin E, Tullio-Pelet A, Begeot F, Lyonnet S, Abel L. Estimating the age of rare 
disease mutations: the example of Triple-A syndrome. J Med Genet. 2004;41:445-
449. 
21. Banin E, Shalev RS, Obolensky A, et al. Retinal function abnormalities in patients 
treated with vigabatrin. Arch Ophthalmol. 2003;121:811-816. 
22. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE. Nonsense-mediated decay 
approaches the clinic. Nat Genet. 2004;36:801-808. 
23. van den Hurk JA, Schwartz M, van Bokhoven H, et al. Molecular basis of 
choroideremia (CHM): mutations involving the Rab escort protein-1 (REP-1) gene. 
Hum Mutat. 1997;9:110-117. 
24. Vervoort R, Lennon A, Bird AC, et al. Mutational hot spot within a new RPGR 
exon in X-linked retinitis pigmentosa. Nature Genetics. 2000;25:462-466. 
Page 17 of 29 IOVS
 18 
25. Vervoort R, Wright AF. Mutations of RPGR in X-linked retinitis pigmentosa (RP3). 
Human Mutation. 2002;19:486-500. 
26. Sharon D, Sandberg MA, Rabe VW, et al. RP2 and RPGR mutations and clinical 
correlations in patients with X-linked retinitis pigmentosa. Am J Hum Genet. 
2003;73:1131-1146. 
27. Abidia O, Boulouiza R, Nahilia H, et al. The analysis of three markers flanking 
GJB2 gene suggests a single origin of the most common 35delG mutation in the 
Moroccan population. Biochemical and Biophysical Research Communications. 
2008;377:971-974. 
28. Mor-Cohen R, Zivelin A, Fromovich-Amit Y, et al. Age estimates of ancestral 
mutations causing factor VII deficiency and Dubin-Johnson syndrome in Iranian 
and Moroccan Jews are consistent with ancient Jewish migrations. Blood Coagul 
Fibrinolysis. 2007;18:139-144. 
 
Page 18 of 29IOVS
 19 
FIGURE LEGENDS 
 
FIGURE 1: Israeli and Palestinian families with EYS mutations. Numbers above the family 
trees indicate the family serial number, numbers within symbols represent the number of 
siblings, numbers below symbols indicate the generation and individual numbers, arrows 
represent index cases, and a double horizontal line designates consanguinity with an 
indication of the consanguinity level (e.g. 2:2 designates first cousin marriages). For each 
recruited individual, the EYS genotype is depicted below the individual symbol. M1- 
p.Thr135LeufsX25, M2- p.Ser1454X, M3- p.Asn404LysfsX2, M4- p.His2740TyrfsX27, 
M5- p.Glu1239X. 
 
FIGURE 2: The chromatograms of the five novel EYS mutations. For each mutation, the 
wild-type (wt) sequence is depicted with the homozygous or heterozygous sequences when 
available. The mutation location is indicated by either an arrow (for a nucleotide change) or 
a horizontal line (for a sequence change affecting more than a single nucleotide).  A- 
c.403delA,406G>T,410_424del15; p.Thr135LeufsX25 (exon 4), B- c.1211_1212insA; 
p.Asn404LysfsX2 (exon 8), C- c.3715G>T; p.Glu1239X (exon 25), D- 
c.4361_4362CC>AG; p.Ser1454X (exon 26), E- c.8218_8219delCA; p.His2740TyrfsX27 
(exon 43).  
 
FIGURE 3: Fundus imaging and visual fields. Representative fundus images and Goldman 
visual fields of the left eyes of patient TB24 III:2 (panels A-D) at age 63 and patient 
MOL0501 II:3 (panels E-H) at age 52 are shown. The typical funduscopic findings of RP 
are present, including bone spicule-like pigmentation, pallor of the optic discs, and 
narrowing of blood vessels (A,E). Macular involvement is evident also on autofluorescence 
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imaging (B,F) and OCT, with retinal thinning and atrophy (D,H). Note more severe foveal 
atrophy in patient MOL0501 II:3 which correlates with the lower visual acuity of this 
patient (Table 2). Visual fields are markedly constricted in both patients (C,G).   
 
FIGURE 4: A graph representing cone 30-Hz ERG amplitude (Y-axis) versus the age (X-
axis) at which ERG data was first obtained from 11 patients with EYS mutations (filled 
diamonds) versus 240 patients diagnosed with RP (open squares). Each data point 
represents the average cone flicker amplitude of the two eyes of each patient. 
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Table 1: Data regarding patients screened for mutations in the EYS gene  
 
Patient number
*
 Inheritance 
pattern and 
clinical 
diagnosis
†
 
Level of 
Consanguinity
‡
 
Origin Number of 
consecutive 
homozygous 
SNPs 
Size of 
homozygous 
region (in Mb 
and cM)
§
 
Rank among 
homozygous 
regions (based 
on genetic size) 
Mutation 1 
Mutation 2  
MOL0139-1 
MOL0139-2 
arRP 
2:1 
2:1 
Moroccan Jew 169 
332 
50 Mb; 39 cM 
90 Mb; 70 cM 
2
nd
 
1
st
 
none 
MOL0144-1 arRP 3:2 Oriental Jew  113 33 Mb; 27 cM 2
nd
 none 
MOL0161-1 sSTGD 2:2 Israeli Muslim 236 60 Mb; 43 cM 1
st
 none 
MOL0260-1 sRP 2:2 Israeli Muslim 277 72 Mb; 53 cM 1
st
 none 
MOL0264-1 sRP 2:2 Israeli Muslim 118 34 Mb; 16 cM 4
th
 none 
MOL0318 II:13 
MOL0318 II:9 
MOL0318 III:2 
MOL0318 III:5  
arRP 2:2 
2:2 
none 
none 
Moroccan Jew 243 
200 
    9 
n.d 
65 Mb; 72 cM 
55 Mb; 49 cM 
3.2Mb;1.5cM 
n.d 
1
st
 
1
st
 
p.Thr135LeufsX25 
p.Thr135LeufsX25 
MOL0399-1 sLCA 2:2 Oriental Jew  396 103 Mb; 80 cM  1
st
 none 
MOL0400-1 sRP 2:2 Ashkenazi Jew 107 30 Mb; 13 cM 3
rd
 none 
MOL0410 II:1 sRP 2:2 Palestinian 
Muslim 
122 37 Mb; 20 cM 5
th
 
p.Ser1454X 
p.Ser1454X 
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MOL0501 II:1 arRP 2:2 Moroccan Jew 175 44 Mb; 24 cM  1
st
 p.Thr135LeufsX25 
p.Thr135LeufsX25 
MOL0615-1 sLCA 2:2 Israeli Muslim 157 42 Mb; 20 cM 1
st
 none 
MOL0626 III:1 arRP none Moroccan Jew n.d n.d n.d p.Thr135LeufsX25 
p.Asn404LysfsX2 
MOL0631-1 arRP 2:2 Moroccan Jew 254 70 Mb; 71 cM 1
st
 none 
MOL0640 II:1 sRP- sector none Iraqi Jew n.d n.d n.d p.His2740TyrfsX27 
p.His2740TyrfsX27 
MOL0652-1 arRP 2:2 Israeli Muslim 102 28 Mb; 18 cM 4
th
 none 
MOL0662 IV:1 sRP 2:2 Moroccan Jew 60 20 Mb; 10 cM 7
th
 p.Thr135LeufsX25 
p.Thr135LeufsX25 
MOL0788-1 sRP 2:2 Ashkenazi Jew 69 24 Mb; 12 cM 9
th
 none 
MOL0792 II:2 sRP 2:2 Moroccan Jew n.d n.d n.d p.Thr135LeufsX25 
p.Thr135LeufsX25 
MOL0806 III:7 arRP 2:1 Moroccan Jew n.d n.d n.d p.Thr135LeufsX25 
p.Thr135LeufsX25 
TB24 III:2 sRP none Moroccan/ Iraqi 
Jew 
n.d n.d n.d 
p.Glu1239X 
p.His2740TyrfsX27 
TB59 III:1 sRP none Iraqi Jew n.d n.d n.d p.Thr135LeufsX25 
p.His2740TyrfsX27 
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*
 In bold are patients in whom EYS mutations were identified. The corresponding family trees are shown in Fig. 1. 
†
 arRP, autosomal recessive retinitis pigmentosa; sRP, simplex retinitis pigmentosa; sSTGD, simplex Stargardt disease; sLCA, simplex Leber’s 
congenital amaurosis. 
‡
 Level of consanguinity is measured by the number of generations separating the spouse from the common ancestor (e.g. 2:2 designates first cousins, 
2:1 designates marriage between an uncle and his niece). 
§ Data are based on 10K SNP analysis (see Materials and Methods). 
  The predicted effect of the mutation on the protein sequence is presented. Please see Supplementary Table for additional information. 
n.d.- not done. 
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Table 2: Clinical data of patients carrying EYS mutations 
Patient 
no. 
Sex 
(age) 
Age of 
diagnosis 
Refraction Visual 
Acuity 
FFERG* 
 
MOL0318 
III:1 
M 
19 
19 NA NA Extinguished 
Extinguished 
MOL0318 
II:  
F 
 
36 Myopia CF 2m 
CF 2m 
Extinguished 
Extinguished 
MOL0318 
II:  
F 
38 
38 -3.50/-1.00 35° 
-5.00/-0.50 160° 
0.3 
0.15 
NP 
MOL0318 
II:  
M 
32 
32 -4.50/-1.00 35° 
-6.00/-0.50 170° 
0.15 
0.15 
NP 
MOL0318 
II:  
F 
 
36 NA NA Extinguished 
Extinguished 
MOL0318 
III:2 
M 
 
19 NA NA Extinguished 
 
MOL0318 
III:  
 
 
18 NA 0.7 
0.7 
  
Extinguished 
MOL0410 
II:1 
M 
 
21 -2.0/-0.25 35° 
-2.0/-1.00 140° 
0.5 
0.8 
Extinguished 
Extinguished 
MOL0501 
II:1 
 
 
33 NA 0.1 
0.25 
 
 
MOL0501 
II:3  
 
 
37 +1.50/-1.00 16° 
+1.50/-0.75 160° 
0.06 
0.05 
NP 
MOL0626
 III:1 
F 
 
50 NA  
 
Extinguished 
Extinguished 
MOL
II:  
M 
47 
20 NA  
0.6 
27; 53/97; 8, 36 
29; 31/81; 7, 36 
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MOL
IV:1 
M 
41 
41 NA 0.15 
0.15 
NP 
MOL
II:2 
M 
 
57 -0.75/-3.00 40° 
-2.50/-1.50 50° 
CF 2.5m 
CF 1m 
NP 
TB24 
III:2 
F 
55 
40 -0.75/-0.25 18° 
+0.25/-1.50 132° 
0.5 
0.4 
Extinguished 
Extinguished 
TB   
III:1 
F 
19 
19 +3.50/-0.75 160° 
+4.25/-0.50 44° 
0.8 
0.8 
Extinguished 
Extinguished 
 
*
 FFERG=Full field electroretinogram including the followings: Rod response b-wave 
amplitude (in V, normal > 200μV); Mixed cone-rod a/b wave (in V, normal a-wave > 
90μV, normal b-wave > 400μV); Cone response (in V, normal > 60μV), implicit time (in 
msec, normal  ≤ 33 msec). 
CF, counting fingers; F, female; M, male; m, meter; NA, Not available; NP, not performed.  
First line (2
nd
 -6
th
 column) indicates the right eye, second line indicates the left eye. 
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FIGURE 1 
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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